Since 2015, ten new brands have launched in the Parkinson’s disease (PD) therapy market (e.g., Inbrija [Acorda], Kynmobi [Sunovion], Ongentys [Neurocrine]), and several more are on the horizon, including AbbVie’s ABBV-951, Amneal’s IPX203, and Addex’s dipraglurant. As developers seek to carve out a clinical role for each of these products, they will introduce additional complexity to a complicated treatment algorithm. New brands have the potential to meaningfully increase the market value, but intensifying competition, coupled with patient and payer cost-sensitivity in a crowded and mostly generic market, creates a challenging launch environment. Generic options are available in every PD drug class, and brands entering these classes will struggle to compete without decisive clinical differentiation. A deep understanding of current and future market dynamics in PD will be critical for new and established players vying for a share of this increasingly competitive landscape.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 25 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Total, diagnosed, and drug-treated prevalent cases of PD by country.
Emerging therapies: Phase II: 20 drugs; Phase III: 6 drugs; preregistration: 1 drug.
Market forecast features: Ten-year, annualized, drug-level sales and patient shares of key PD therapies through 2030, segmented by brands / generics.
Key companies: AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Addex Therapeutics, Amneal Pharmaceuticals, Cerevel Therapeutics, Eisai, Hisamitsu Pharmaceutical, Kyowa Kirin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, NeuroDerm, Osmotica Pharmaceuticals, Pharma Two B, Sumitomo Dainippon Pharma, Sunovion, Takeda, Teva, Theravance Biopharma, UCB, US WorldMeds, Zambon Pharma.
Key drugs: levodopa, amantadine, ampreloxetine, apomorphine, ABBV-951, AP-CD/LD, Duodopa / Duopa, dipraglurant, entacapone, Gocovri, Haruropi Tape, Inbrija, IPX203, Kynmobi, Lecigon, ND0612, Neupro, Nourianz, Nuplazid, Ongentys, Osmolex ER, pramipexole, P2B001, rasagiline, ropinirole, Rytary, selegiline, tavapadon, Trerief, Xadago.
Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.